Neratinib in HER2-Positive Breast Cancer Patients

Treatment of advanced HER2-positive breast cancer: 2018 and beyond

(2018) Noam Pondé et al.   CANCER TREATMENT REVIEWS

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

(2018) Neelima Denduluri et al.   JOURNAL OF CLINICAL ONCOLOGY

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

(2017) David Cameron et al.   LANCET

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Miguel Martin et al.   LANCET ONCOLOGY

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects

(2016) Kiana Keyvanjah et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Human epidermal growth factor antagonists and cardiotoxicity—A short review of the problem and preventative measures

(2016) A. Dias et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

(2016) Rachel A. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Arlene Chan et al.   LANCET ONCOLOGY

Adaptive Randomization of Neratinib in Early Breast Cancer

(2016) John W. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

(2016) Ahmad Awada et al.   JAMA Oncology

Targeted therapies for ER+/HER2- metastatic breast cancer

(2015) Mutsuko Yamamoto-Ibusuki et al.   BMC Medicine

HER2 in Breast Cancer

(2014) Uma Krishnamurti et al.   ADVANCES IN ANATOMIC PATHOLOGY

Trastuzumab emtansine: mechanisms of action and drug resistance

(2014) Mark Barok et al.   BREAST CANCER RESEARCH

Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2014) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab

(2013) W. J. Gradishar   ANNALS OF ONCOLOGY

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

(2013) Mario Giuliano et al.   Breast Care

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

(2013) L W-C Chow et al.   BRITISH JOURNAL OF CANCER

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

(2013) Rachel C. Jankowitz et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A systematic review of dual targeting in HER2-positive breast cancer

(2013) Iben Kümler et al.   CANCER TREATMENT REVIEWS

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer

(2013) Miguel Martin et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy

(2012) A. Awada et al.   ANNALS OF ONCOLOGY

Neratinib (HKI-272) in the treatment of breast cancer

(2012) Sara López-Tarruella et al.   Future Oncology

Safety, Efficacy and Pharmacokinetics of Neratinib (HKI-272) in Japanese Patients with Advanced Solid Tumors: A Phase 1 Dose-escalation Study

(2012) Y. Ito et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation

(2011) Qinghong Lu et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects

(2010) Richat Abbas et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

(2010) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

(2008) Allan Wissner et al.   ARCHIV DER PHARMAZIE